Click here to view the October 2021 edition of Dates for Your Diary

TOKYO and NOTTINGHAM, UK |21 October 2021 - Astellas Venture Management LLC, a wholly-owned venture capital subsidiary of Astellas Pharma Inc, and We are Pioneer Group (WAPG), the UK’s largest ecosystem provider for science and innovation businesses, today announce a new collaborative sponsorship and first of its kind initiative to support early stage science ventures. 

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.

Cambridge, UK, 20 October 2021:  Mursla, a liquid biopsy company, is delighted to announce that it has been granted patent GB 2583550B for its novel nanoelectronics-based sensitive detection method for exosomes.


Leading biotech product development consultancy Boyds has added two experienced product development experts to its team, amid growing demand for specialist Product Development services from clients in the UK, Europe and the US.

Diane Shattock Ph.D., joins as Director of Product Development and Ian Hollingsworth M.Sc., as Associate Director of Product Development. Both are working alongside Boyds’ Vice President of Product Development, Nick Meyers Ph.D.

The UK’s Patents Court has recently handed down judgment in Royalty Pharma Collection Trust v Boehringer Ingelheim GmbH . This author will not get into the detail since the case concerned German law – but it is clear that interesting points on patent licensing and substantive patent law feature extensively.

ALAMEDA, Calif. & CAMBRIDGE, UK – October 14, 2021 – Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

In a lengthy and complex decision reaching over 80 pages and one that will be welcomed by holders of standard essential patents (SEPs), Mr Justice Meade has given judgment in the latest in a series of trials in the UK’s Patents Court between Optis and Apple concerning Optis’ SEPs and the FRAND obligations which apply to them. Two previous trials had established that two of Optis’ SEPs were valid, essential and infringed. One of those patents had expired, the other had not.

The International Energy Agency (IEA) released its World Energy Outlook 2021 (WEO-2021) on 13 October 2021. As widely predicted, 2021 saw a large rebound in coil and oil use resulting in the second-largest annual increase in CO2 emissions in history. While financial commitments have been made towards reaching the IEA’s Net Zero Emissions 2050 scenario, public spending on sustainable energy has only mobilized an estimated one-third of the required investment.

RoslinCT developing life-changing gene and cell therapies in Edinburgh’s BioQuarter-Company has doubled its workforce in the last year and plans 25% more jobs by end of 2021

A new state-of-the-art cell and gene therapy manufacturing facility in Edinburgh has been formally opened by Ian McCubbin CBE on behalf of Sir Patrick Vallance, the Chief Scientific Adviser to the UK government.